Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on Equity

Lyell Immunopharma (LYEL) Return on Assets: 2021-2025

Historic Return on Assets for Lyell Immunopharma (LYEL) over the last 4 years, with Sep 2025 value amounting to -0.83%.

  • Lyell Immunopharma's Return on Assets fell 53.00% to -0.83% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.83%, marking a year-over-year decrease of 53.00%. This contributed to the annual value of -0.54% for FY2024, which is 27.00% down from last year.
  • Per Lyell Immunopharma's latest filing, its Return on Assets stood at -0.83% for Q3 2025, which was up 0.46% from -0.83% recorded in Q2 2025.
  • Lyell Immunopharma's Return on Assets' 5-year high stood at -0.17% during Q3 2021, with a 5-year trough of -0.83% in Q2 2025.
  • Over the past 3 years, Lyell Immunopharma's median Return on Assets value was -0.30% (recorded in 2024), while the average stood at -0.44%.
  • As far as peak fluctuations go, Lyell Immunopharma's Return on Assets grew by 2bps in 2023, and later slumped by 53bps in 2025.
  • Over the past 5 years, Lyell Immunopharma's Return on Assets (Quarterly) stood at -0.18% in 2021, then remained steady at -0.19% in 2022, then decreased by 10bps to -0.29% in 2023, then crashed by 31bps to -0.60% in 2024, then crashed by 53bps to -0.83% in 2025.
  • Its Return on Assets stands at -0.83% for Q3 2025, versus -0.83% for Q2 2025 and -0.74% for Q1 2025.